TFFP TFF Pharmaceuticals
- 2.0900
- -0.1100-5.00%
- 2.0900
- 0.00000.00%
TFF Pharmaceuticals News
Express News | TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering
TFF Pharmaceuticals Prices $4.8 Million Public Offering; Shares Down Pre-Bell
TFF Pharmaceuticals (TFFP) said late Monday it priced a public offering of about 1.7 million common shares and warrants to purchase up to about 1.7 million shares at a combined price of $2.875 per sha
Reported Earlier, TFF Pharmaceuticals Prices $4.8M Public Offering Of 1,665,219 Shares And Warrants At $2.875/Share Accompanying Warrant
TFF Pharmaceuticals announced the pricing of a public offering of an aggregate of 1,665,219 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 1,66
Express News | TFF Pharmaceuticals Inc- Pricing of Public Offering of Aggregate of 1.67 Mln Shares of Common Stock and Warrants at Combined Price of $2.875 per Share
Express News | TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
TFF Pharmaceuticals' 1.7 Million-Share Offering Prices at $2.875 a Share >TFFP
TFF Pharmaceuticals' 1.7 Million-Share Offering Prices at $2.875 a Share >TFFP
Express News | TFF Pharmaceuticals Inc - Assumed Public Offering Price for Each Share of Common Stock and Accompanying Series B Warrant Is $3.05
Express News | TFF Pharmaceuticals Files for Offering of up to 2.6 Mln Shares of Common Stock, Together With Series B Common Stock Purchase Warrants
TFF Pharmaceuticals Signals Advancements in Investor Update
Express News | TFF Pharmaceuticals Inc: Plans to Open an Ind in US to Explore Use of TFF Tac Early Post-Transplant in Preparation for a Registrational Trial
Express News | TFF Pharmaceuticals Inc: No TFF Tac Discontinuation Due to an Ae
Express News | TFF Pharmaceuticals Inc: Successful Transition of Eight of Eight Patients From Oral Tacrolimus to TFF Tac
Express News | TFF Pharmaceuticals Announces Additional Positive Data From the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation at the Ishlt 44TH Annual Late Breaking Clinical Science Abstract Sessions
TFF Pharmaceuticals Files to Sell Common Stock, Warrants
Analysts' Top Healthcare Picks: ADC Therapeutics (ADCT), TFF Pharmaceuticals (TFFP)
TFF Pharmaceuticals GAAP EPS of -$2.01, Revenue of $0.1M
TFF Pharmaceuticals Q4 EPS $(2.01) Beats $(2.12) Estimate, Sales $114.33K Beat $100.00K Estimate
TFF Pharmaceuticals (NASDAQ:TFFP) reported quarterly losses of $(2.01) per share which beat the analyst consensus estimate of $(2.12) by 5.19 percent. This is a 19.6 percent increase over losses of $(
Earnings Flash (TFFP) TFF PHARMACEUTICALS Reports Q4 Revenue $114.3M
04:05 PM EDT, 03/28/2024 (MT Newswires) -- Earnings Flash (TFFP) TFF PHARMACEUTICALS Reports Q4 Revenue $114.3M
Press Release: TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results FORT WORTH, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) ("the Company"), a clini
TFF Pharmaceuticals 4Q Loss/Shr $2.01 >TFFP
TFF Pharmaceuticals 4Q Loss/Shr $2.01 >TFFP
Analysis
Price Target
No Data
